GGrantIndex
← Search

Research Pharmacy

$275,834P30FY2022CANIH

Johns Hopkins University, Baltimore MD

Investigators

Linked publications, trials & patents

Trial NCT02989636Trial NCT02516670Trial NCT02491411Trial NCT02489357Trial NCT02029950Trial NCT01935947Trial NCT01870596Trial NCT01783171Trial NCT01757639Trial NCT01578109Trial NCT01349972Trial NCT01349959Trial NCT01330173Trial NCT01264432Trial NCT01207726Trial NCT01207687Trial NCT01139970Trial NCT01132573Trial NCT01061749Trial NCT00971737Trial NCT00963807Trial NCT00899951Trial NCT00899548Trial NCT00898482Trial NCT00897338Trial NCT00897273Trial NCT00847171Trial NCT00795002Trial NCT00727441Trial NCT00673569Trial NCT00670917Trial NCT00660348Trial NCT00641303Trial NCT00641147Trial NCT00631137Trial NCT00616967Trial NCT00602771Trial NCT00588991Trial NCT00566098Trial NCT00524017Trial NCT00499733Trial NCT00499486Trial NCT00493025Trial NCT00492921Trial NCT00489281Trial NCT00478062Trial NCT00478010Trial NCT00471653Trial NCT00470093Trial NCT00469820Trial NCT00445484Trial NCT00433472Trial NCT00425477Trial NCT00407966Trial NCT00401024Trial NCT00389610Trial NCT00387465Trial NCT00381550Trial NCT00373191Trial NCT00369681Trial NCT00368914Trial NCT00363649Trial NCT00361296Trial NCT00356928Trial NCT00354640Trial NCT00343447Trial NCT00336063Trial NCT00334542Trial NCT00324870Trial NCT00313560Trial NCT00311623Trial NCT00305760Trial NCT00303927Trial NCT00293410Trial NCT00293397Trial NCT00293280Trial NCT00290732Trial NCT00287989Trial NCT00287872Trial NCT00281970Trial NCT00281866Trial NCT00278200Trial NCT00278161Trial NCT00278109Trial NCT00276744Trial NCT00276601Trial NCT00276588Trial NCT00274768Trial NCT00265915Trial NCT00265837Trial NCT00262834Trial NCT00258206Trial NCT00258180Trial NCT00255775Trial NCT00255710Trial NCT00245115Trial NCT00244959Trial NCT00242996Trial NCT00238368Trial NCT00238277

Abstract

PROJECT SUMMARY/ABSTRACT The Research Pharmacy (Investigational Drug Service-IDS) Shared Resource (SR) was established to support inpatient and outpatient clinical research conducted by investigators at the Sidney Kimmel Comprehensive Cancer Center (SKCCC). The Research Pharmacy staff work in close collaboration with the SKCCC Clinical Research Office, disease groups, individual investigators and the Weinberg Oncology Pharmacy clinical staff to coordinate and facilitate the development, implementation and maintenance of clinical trial protocols. Services provided by the Research Pharmacy include protocol consultation, clinical data monitoring, investigational product management, participation in the electronic order set development process, monitoring patient investigational product adherence, providing quality assurance activities, providing drug information and drug-drug interaction reviews, IRB membership and resources to disease groups, and other services to support the study teams. This SR is fully integrated within the SKCCC Oncology Pharmacy and is an integral part of the SKCCC's research efforts. This integration allows for additional support to research participants by incorporating pharmacy clinical specialists' expertise and collaboration with Oncology Pharmacy staff and technology to support production. The SR staff include a Pharmacy Division Director, an Operations Manager, four Clinical Research Pharmacists, one Clinical Decision Support Pharmacist, two Certified Pharmacy Technicians and one Certified Pharmacy Technician/Inventory Specialist. Pharmacy support is available to investigators and the research teams for patient care services 24/7. The Research Pharmacy is compliant with Maryland Board of Pharmacy regulations, United States Pharmacopeia (USP) Chapter 797, pharmaceutical sterile compounding regulations, and with state, federal and Johns Hopkins Medicine Institutional Review Board regulations for the conduct of research. Compliance with USP Chapter <800> will be fully instituted at the completion of upcoming pharmacy renovations planned for fall 2021. Current areas of focus to improve services and provide exceptional care to oncology study participants include medication safety initiatives, exploring new technology and innovative practices, implementing clinical pharmacy services within the Developmental Therapeutics Clinical Research Group (Phase I), supporting research expansion initiatives, and facilitating residency training of a nationally accredited pharmacy residency program for investigational drugs and research. SKCCC Managed Shared Resource Reporting Period: January 1, 2020 to December 31, 2020

View original record on NIH RePORTER →